Tanzania ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

Tanzania Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The Tanzania Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $12 Mn in 2022 and is projected to reach $23 Mn in 2030, exhibiting a CAGR of 8.4% during the forecast period. Tanzania has a weak healthcare infrastructure, limited resources, and high rates of maternal and infant mortality, HIV/AIDS, pneumonia, and malaria. The general population of Tanzania also has some of the lowest rates of worldwide access to medical professionals. In 2020–21, the government of Tanzania allotted $387.9 Mn for the health sector, of which $155.5 Mn was spent on development projects to aid in the implementation of the country's policies aimed at enhancing public health.  In 2022/23, the industry received $470 Mn. International donors who give up to 40% of the health budget supplement the financing of healthcare. Through USAID and CDC, the US government makes a sizable contribution to initiatives that help the Tanzanian government. Only 32% of Tanzanians had health insurance as of 2019; this indicates the country's poor level of health insurance coverage.  Only 1% of those people have private health insurance.

The most prevalent neurobehavioral childhood condition, Attention Deficit Hyperactivity condition (ADHD), manifests between the ages of 3 and 7 and is characterized by impulsivity, hyperactivity, and inattention. In Tanzania, it affects 2.2 to 17.8% of all school-age children and teenagers. Children with ADHD suffer negative consequences at home and at school. It causes agitation, reckless behavior, and lack of concentration, which could harm the child's performance. These symptoms are difficult to manage, especially for parents with limited knowledge and comprehension of the outcomes for the child. Treatments in Tanzania combine medication, psychotherapy, instruction, and information. Adult patients may receive medical care, psychoanalysis, counseling, education, or training. The most popular and well-known ADHD treatments are stimulants. When taking these medications with an immediate effect, 70 to 80 % of adolescents with ADHD experience fewer symptoms. Tanzania has authorized the use of non-stimulants for the therapy of ADHD. Although they do not work as rapidly as stimulants, they can still have an impact for up to 24 hours.

Market Dynamics

Market Growth Drivers

Tanzania is experiencing a rise in the incidence of ADHD, which is fuelling the Tanzania ADHD therapeutics market's expansion. Although the precise causes are unknown, variables like dietary changes, lifestyle changes, and environmental factors may be adding to the increase in prevalence.

Market Restraints

Tanzania is becoming more aware of ADHD, but many communities there still don't comprehend the disorder. Delays in diagnosis and therapy may result from this, which may have an effect on the market's expansion. Due to Tanzania's limited healthcare means, it may be difficult to diagnose and treat ADHD patients. There might be an extended wait to see a specialist, and many people might find the cost of treatment to be unaffordable. ADHD medications are frequently controlled drugs, so Tanzania may not have easy access to them. The capacity of medical professionals to prescribe medication may be affected by this, which may also restrict the Tanzania ADHD therapeutics market expansion.

Competitive Landscape

Key Players

• Abacus Chemists (TZA)
• Afya Laboratories (TZA)
• Biocare Health Products (TZA)
• Continental Pharma (TZA)
• Fern Pharmaceuticals (TZA)
• Purdue Pharma
• RespireRx Pharmaceuticals
• Supernus Pharmaceuticals
• Takeda Pharmaceutical
• Tris Pharma

Healthcare Policies and Regulatory Landscape

An executive agency under the Ministry of Health, Community Development, Gender, Elderly, and Children (MOHCDGE) is Tanzania Medicines and Medical Devices Authority (TMDA). The TMDA is in charge of overseeing the security, caliber, and efficacy of pharmaceuticals, medical equipment, and tests. The Tanzania Food, Drugs, and Cosmetics Act (TFDCA) cap. 219 as amended by the Finance Act of 2019 specifies the TMDA's mandate and outlines its primary responsibilities. The act outlines effective and thorough regulations and controls for the security and caliber of medications, medical equipment, and diagnostics on Tanzania's mainland. The TMDA is run as an Executive Agency in accordance with the 2009 amendments to the Executive Agencies Act, cap. 245, in order to enhance the delivery of public services.

The Tanzania Medicines and Medical Devices Authority (TMDA) has the following responsibilities to safeguard and advance public health: It is assessed both domestically produced products and services as well as imports for the quality, safety, and efficacy of human and veterinary medicines, herbal medicines, medical devices, and diagnostics. The TMDA should register the premises and issue a Premises Registration Certificate to any location intended to be used for the manufacture, storage, or sale of regulated products. Products that are subject to TMDA regulation must be registered and issued with a Product Registration Certificate after they are made or imported into the nation in order to be permitted to be sold. Once their facilities and goods have been listed, all TMDA-regulated product manufacturers and dealers should receive a TMDA Business Permit.